文献速递类风湿关节炎

氨甲酰化白蛋白是抗氨甲酰化蛋白抗体的靶抗原之一

Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

研究通过Western blotting发现氨甲酰化白蛋白是抗CarP抗体的靶抗原,并在493例RA患者和144例健康对照中检测抗CarALB抗体,31.4%的RA患者阳性,且与抗CarP抗体滴度高度相关。抑制ELISA显示抗CarP抗体可被CarALB抑制而非citALB,血清CarALB可通过LC/MS/MS检测,且抗CarALB阳性者MPO浓度更高。

要点

  • 氨甲酰化白蛋白是抗CarP抗体的新靶抗原,非ACPA已知靶点。
  • 31.4%的RA患者可检测到抗CarALB抗体。
  • 抗CarALB与抗CarP抗体滴度相关性高于抗citALB与抗CCP抗体。

核心结论

  • 氨甲酰化白蛋白是抗CarP抗体的新靶抗原,且为首个非ACPA已知靶点的报道。

研究设计与样本

  • 研究先通过Western blotting检测抗CarP抗体,再用in-house ELISA检测493例RA患者和144例健康对照的抗CarALB抗体。

主要发现

  • 抗CarALB抗体在31.4%的RA患者中可检测到。
  • 抗CarALB与抗CarP抗体滴度的相关性(ρ=0.59)高于抗citALB与抗CCP抗体的相关性(ρ=0.16)。
  • 抑制ELISA显示抗CarP抗体可被CarALB抑制,但不被citALB抑制。
  • LC/MS/MS可在RA患者血清中检测到CarALB。
  • 抗CarALB抗体阳性RA患者的血清MPO浓度高于阴性者,且MPO浓度与疾病活动度相关。

关键数值与推荐

  • 抗CarALB抗体在RA患者中的阳性率为31.4%。
  • 抗CarALB与抗CarP抗体滴度的相关系数ρ=0.59,抗citALB与抗CCP抗体的ρ=0.16。

临床怎么用

  • 抗CarALB抗体检测可能作为RA血清学标志物,尤其与抗CarP抗体相关。
  • 抗CarALB阳性与更高MPO浓度相关,提示其可能与疾病活动度相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-carbamylated protein (anti-CarP) antibodies are detected in RA patients. Fetal calf serum is used as an antigen source in anti-CarP ELISA, and the precise target antigens have not been found. We aimed to identify the target antigens of anti-CarP antibodies. METHODS: Western blotting of anti-CarP antibodies was conducted. Anti-carbamylated human albumin (CarALB) antibody was detected by in-house ELISA for 493 RA patients and 144 healthy controls (HCs). An inhibition ELISA of anti-CarP antibodies by CarALB and citrullinated albumin (citALB) was performed using eight RA patients' sera. Serum CarALB was detected by liquid chromatography-tandem mass spectroscopy (LC/MS/MS), and the serum MPO concentration was measured by ELISA. RESULTS: We focused on carbamylated albumin because it corresponded to the size of the thickest band detected by western blotting of anti-CarP antibodies. Anti-CarALB antibody was detected in 31.4% of RA patients, and the correlation of the titres between anti-CarALB and anti-CarP was much closer than that between anti-citALB and anti-CCP antibodies (ρ = 0.59 and ρ = 0.16, respectively). The inhibition ELISA showed that anti-CarP antibodies were inhibited by CarALB, but not by citALB. CarALB was detected in sera from RA patients by LC/MS/MS. The serum MPO concentration was correlated with disease activity and was higher in RA patients with anti-CarALB antibody than in those without. CONCLUSION: We found that carbamylated albumin is a novel target antigen of anti-CarP antibodies, and it is the first reported target antigen that has not been reported as the target of ACPA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nakabo S, Hashimoto M, Ito S, et al. Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Rheumatology (Oxford). 2017. PMID: 28398552. doi:10.1093/rheumatology/kex088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。